Heron Therapeutics, Inc. (HRTX) News
Follow Heron Therapeutics, Inc. (HRTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Heron Therapeutics Q3 Revenue Falls 7.8%; to Sell Assets to CorMedix
Heron Therapeutics reported a 7.8% decline in third-quarter net revenue and plans to sell all its assets to CorMedix.
EQUITY | Nov 09, 2026, 01:41 PM UTC
M
CorMedix, Heron transaction upfront consideration totals about $222.6 million
MNA | Nov 09, 2026, 12:22 PM UTC
M
CorMedix to Acquire Substantially All Heron Therapeutics Assets
The transaction adds four commercial-stage products to CorMedix’s hospital- and acute-care-focused platform. Consideration includes $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 C
EQUITY | Nov 09, 2026, 12:17 PM UTC
M
Heron Therapeutics to Report Third-Quarter Results
Heron Therapeutics says it will report third-quarter financial results.
EQUITY | Oct 27, 2026, 12:10 AM UTC
L
Heron Therapeutics Inks Multi-Product U.S. License With Long Grove, 10-Year Term Plus Renewals
Heron Therapeutics entered a multi-product Development and License Agreement to commercialize certain products in the United States. The deal grants Heron an exclusive U.S. license to import, distribute, sell and market
NEWS | Sep 29, 2026, 09:03 PM UTC